- Home
- MIRM vs FITBO Comparison
MIRM vs FITBO Comparison
Compare MIRM & FITBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIRM | FITBO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | 18616 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | N/A |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MIRM | FITBO |
|---|---|---|
| Price | $90.21 | $19.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $114.67 | N/A |
| AVG Volume (30 Days) | ★ 688.0K | 16.2K |
| Earning Date | 05-18-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,138,000.00 | N/A |
| Revenue This Year | $24.61 | N/A |
| Revenue Next Year | $21.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.88 | $19.19 |
| 52 Week High | $109.28 | $22.80 |
Technical Indicators
Market Signals| Indicator | MIRM | FITBO |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 34.95 |
| Support Level | $85.76 | $19.20 |
| Resistance Level | $107.51 | $19.85 |
| Average True Range (ATR) | 4.07 | 0.14 |
| MACD | -0.94 | -0.05 |
| Stochastic Oscillator | 19.09 | 7.94 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About FITBO Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K
Fifth Third Bancorp is a midsize regional bank in the US, with total assets of over $210 billion as of December 2025. The bank is set to close its acquisition of Comercia on Feb. 1, 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.